Journals / Klinik Psikofarmakoloji Bülteni / 2002 / Cilt: 12 - Sayı: 3

The effectiveness and tolerability of citalopram in a Turkish sample of children with obsessive compulsive disorder

Pages
134–141
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: These results suggested that citalopram has seemed to be quite effective and tolerable of child and adolescent with OCD, and comorbid anxiety disorders.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of the study was to describe efficacy, tolerability and side effects of citalopram in the treatment of child and adolescent obsessive-compulsive disorder (OCD).
📊
Key Findings & Data:Methods: This open-label trial of citalopram (10-20 mg daily) included 23 cases.
💡
Conclusion & Impact:Conclusions: These results suggested that citalopram has seemed to be quite effective and tolerable of child and adolescent with OCD, and comorbid anxiety disorders.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of the study was to describe efficacy, tolerability and side effects of citalopram in the treatment of child and adolescent obsessive-compulsive disorder (OCD). Methods: This open-label trial of citalopram (10-20 mg daily) included 23 cases. Maudsley Obsessive Compulsive Questionnaire (MOCQ), Child Depression Inventory (CDI), State and Trait Anxiety Inventory for Children (STAI-C) were given to all children during the detailed psychiatric interviews. The treatment response was evaluated using Clinical Global Improvement Scales (CGI). All cases were assessed by Diagnostic and Statistical Manual of Mental Disorder-Text Revision (DSM-IV-TR). Results: After the 8 weeks of citalopram treatment, statistically significant improvements were found in all scores. 20 subjects (86.95%) had comorbid diagnosis or conditions. Depression was the most common comorbid diagnosis (6 cases, 26.08%). 1 3 subjects (56.52%) had side effects, and all side effects were highly similar to those reported from the use of other selective serotonin reuptake inhibitors (SSRIs). However, sedation during the day-time was obvious in 5 of the cases (21.73%) during the first week. None the subjects worsened during citalopram treatment and none was excluded because of serious side effects during 8 weeks. Conclusions: These results suggested that citalopram has seemed to be quite effective and tolerable of child and adolescent with OCD, and comorbid anxiety disorders.

🔖

Cite This Article

TOROS, F., TATAROĞLU, C., DİLER, R. S. (2022). The effectiveness and tolerability of citalopram in a Turkish sample of children with obsessive compulsive disorder. Klinik Psikofarmakoloji Bülteni, Cilt: 12 - Sayı: 3, 134–141. https://ajindex.com/articles/574522

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Birmaher B," Yelovich AK, Renaud J. Pharmacologic treatment for children and adolescents with anxiety disorders. Ped Clin N Am 1998;45:1187-1200
  2. Murphy TK, Bengtson MA, Tan JY, Carbonell E, Leyin GM. Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: Review. Int Clin Psychopharmacol 2000;5 (Suppl 2):4>63
  3. Grados MA, Riddle MA. Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice. J Clin Child Psychol 2001;30:110-113
  4. Towbin KE, Riddle MA. Obsessive-Compulsive disorder. In: Lewis M, editör Child and Adolescent Psychiatry. A Comprehensive Textbook. Williams & Wilkins, 1996:684-693
  5. Flament MF, Whitaker A, Rapoport JL, Davies M, Berg CZ, Kalikow K, Sceery W, Shaffer D. Obsessive-compulsive disorder in adolescence: an epidemiological study, J Am Acad Child Adolesc Psychiatry 1988;27:764-771
  6. Rapoport JL, Swedo S, Leonard H. Obsessive-compulsive dis¬ order. In: Rutter M, Taylor E, Hersov L (eds). Child and Adolescent Psychiatry, Modern Approaches, London: Blackwell Science Ltd, 1994:441-451
  7. Thomsen PH. Obsession trauma fear panic obsession impulsiv- ity. Pfizer Pharmaceuticals 1998;Copenhagen:30-34
  8. Thomsen PH, Ebbesen C, Persson C. Long-term experience with citalopram in the treatment of adolescent OCD. J Am Acad Child Adolesc Psychiatry 2001;40:895-902
  9. Aberg-Wistedt A. The antidepressant effects of 5-HT uptake inhibitors. Br J Psychiatr 1989;(Suppl 8):32-40
  10. Asberg M, Martensson B. Serotonin selective antidepressant drugs: past, present, future. Clin Neurophamnacol 1993; 16 Suppl 3:32-44
  11. Montgomery SA, Rasmussen JGC, Tanghoj. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-188
  12. DeVane CL, Sallee FR. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 1996;57:55-66
  13. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: An update. Harv Rev Psychiatry 1996;7:69-84
  14. Sounrander A. Case study: Selective serotonin reuptake inhibitors in the treatment of severely disturbed preadolescents with comorbid diagnosis. Nord J Psychiatry 1999;53:431-433
  15. Pato MT. Beyond depression: citalopram for obsessive-compulsive disorder. Int Clin Psychopharmacol 1999; 14 Suppl 2:19-26
  16. Thomsen PH, Rasmussen G, Andersson CB. Elective mutism: 17 year old girl